Effect of alpha-humulene incorporation on the properties of experimental light-cured periodontal dressings

Abstract

The objective of this study was to formulate an experimental light-cured periodontal dressing containing alpha-humulene and to compare its physical, antimicrobial, and cytotoxicity properties with commercial gold standards (Barricaid ® and Periobond ® ). Two periodontal dressing formulations were developed (a and b). The formulations were divided into 5 groups according to the alpha-humulene concentration as follows: Ea -control group, Ea 1 -1%, Ea 5 -5%, Ea 10 -10%, and Ea 20 -20%; Eb -control group, Eb 1 -1%, Eb 5 -5%, Eb 10 -10%, and Eb 20 -20%. Materials characterization was performed using the degree of conversion, cohesive strength, sorption, and solubility assays. Antimicrobial assay was performed using the modified direct contact test against E. faecalis and S. aureus. Cytotoxicity was assessed by the cell viability experiment using L929 fibroblasts. In general, the cohesive strength values of materials decreased as the alpha-humulene concentration increased. All the experimental dressings showed antimicrobial activity against both bacteria tested. Cell viability results for the Ea, Ea 1 , Eb, and Eb 1 groups showed moderate cytotoxic effect. The formulations containing alpha-humulene showed similar behavior to the commercial references. Thus, formulations containing alpha-humulene have potential to be used as periodontal dressing.

The Clinical Translation of α-humulene – A Scoping Review

“…Thirty-two studies were included for evaluation of the pre-clinical properties of α-humulene. These included investigations conducted in vitro [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30], in vivo [31][32][33][34][35][36], and combined in vitro and in vivo experiments [37][38][39][40][41][42]. Notably, no studies were found to assess the clinical properties of α-humulene.…”

“…Thirty-two studies 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 were included for evaluation of the pre-clinical properties of α -humulene. These included investigations conducted in vitro 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , in vivo 31 , 32 , 33 , 34 , 35 , 36 , and combined in vitro and in vivo experiments 37 , 38 , 39 , 40 , 41 , 42 . Notably, no studies were found to assess the clinical properties of α -h...…”

“…Moreover, confocal laser scanning microscopy revealed that α -humulene not only diminished cell density and thickness but also effectively reduced protein, carbohydrate, and nucleic acid levels. Rossato et al (2022) 26 evaluated α -humuleneʼs antibacterial potential against Staphylococcus aureus and Enterococcus faecalis using experimental light-cured periodontal dressing formulations and the modified direct contact model. Formulations with 10% and 20% α -humulene reduced bacterial growth after 1 and 24 hours of incubation compared to the control group, indicating sustained antibacterial activity.…”

“…Rossato et al (2022) [26] evaluated α-humuleneʼs antibacterial potential against Staphylococcus aureus and Enterococcus faecalis using experimental light-cured periodontal dressing formulations and the modified direct contact model. Formulations with 10 % and 20 % α-humulene reduced bacterial growth after 1 and 24 hours of incubation compared to the control group, indicating sustained antibacterial activity.Xing et al (…”